L-methylfolate
Phase 3Small molecule
L-methylfolate is one of 28 small molecule programs targeting Major Depressive Episode. It is currently in Phase 3.
2
Indications
3
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
23 competitors in Generalized Anxiety Disorder
#DrugCompanyPhaseTrials
1Lexapro
AbbVieApproved
Cymbalta
Jazz PharmaceuticalsApproved
Buspar
Bristol-Myers SquibbApproved
Paxil
SSebela Pharmaceuticals Development LLC
Approved
Geodon
PfizerApproved
Ativan
BBausch Health Americas, Inc.
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lunesta
Akero TherapeuticsApproved
Xanax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Zoloft
VViatris Specialty LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Major Depressive Episode1 trial
Generalized Anxiety Disorder1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for L-methylfolate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMassachusetts General Hospital